Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABOSTO:DMYD B +0.97%39 PS Ratio is 346.67 as of Sep. 07, 2026, which is 75% below its 10-year median of 1,410.22. GuruFocus rates OSTO:DMYD B with a GF Score™ of 39/100 and a GF Value™ of kr13.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 937 Biotechnology companies, Diamyd Medical AB ranks worse than 91.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Diamyd Medical AB's share price is kr1.04.
Diamyd Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was kr0.00. Hence, Diamyd Medical AB's PS Ratio for today is 346.67.
Good Sign:
Diamyd Medical AB stock PS Ratio (=346.67) is close to 5-year low of 334.
The historical rank and industry rank for Diamyd Medical AB's PS Ratio or its related term are showing as below:
OSTO:DMYD B'
s PS Ratio Range Over the Past 10 Years
Min: 113.9 Med: 1410.22 Max: 18075.74
Current: 346.67
During the past 13 years, Diamyd Medical AB's highest PS Ratio was 18075.74. The lowest was 113.90. And the median was 1410.22.
OSTO:DMYD B's PS Ratio is ranked worse than 91.78% of 937
companies
in the Biotechnology industry
Industry Median: 9.66
vs OSTO:DMYD B: 346.67
Diamyd Medical AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Diamyd Medical AB was 200.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -45.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -29.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -27.20% per year.
During the past 13 years, Diamyd Medical AB's highest 3-Year average Revenue per Share Growth Rate was 63.00% per year. The lowest was -87.30% per year. And the median was -32.50% per year.
Diamyd Medical AB (OSTO:DMYD B) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Diamyd Medical AB PS Ratio Related Terms
Diamyd Medical AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:DMYD B vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Diamyd Medical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Diamyd Medical AB's Share Price of today is kr1.04. Diamyd Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Diamyd Medical AB (OSTO:DMYD B) has a PS Ratio of 346.67 as of Sep. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diamyd Medical AB and its competitors. This is 75% below median its historical median of 1,410.22. Over the past decade, Diamyd Medical AB's PS Ratio has ranged from 113.90 to 18,075.74. According to the industry distribution chart, Diamyd Medical AB ranks #860 out of 937 companies in the Biotechnology industry, placing it in the top 91.8%.
Is Diamyd Medical AB's PS Ratio too high?
Diamyd Medical AB's current PS Ratio of 346.67 is 75% below median its 10-year median of 1,410.22. Over the past 10 years, this metric has ranged from a low of 113.90 to a high of 18,075.74. The Biotechnology industry median PS Ratio is 9.66. Diamyd Medical AB's value of 346.67 is 3488.7% above this industry median. Based on the distribution chart, Diamyd Medical AB ranks #860 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #860 out of 937 companies for PS Ratio. This places Diamyd Medical AB in the lower half of its industry. The industry median PS Ratio is 9.66. Diamyd Medical AB's value of 346.67 is 3488.7% above this benchmark. Historically, Diamyd Medical AB's own PS Ratio has ranged from 113.90 to 18,075.74 over the past decade. While the company's 10-year median is 1,410.22 vs. the industry median of 9.66, Diamyd Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current PS Ratio of 346.67 is 3488.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current PS Ratio is 346.67, which is 75% below median its own 10-year median of 1,410.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (OSTO:DMYD B) is currently considered Possible Value Trap. The stock's GF Value™ is kr13.41, compared to a current price of kr1.04 — trading 92.2% below its estimated fair value. The current PS Ratio is 346.67, which is 75% below median its 10-year median of 1,410.22 and 3488.7% above the Biotechnology industry median of 9.66. Diamyd Medical AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Diamyd Medical AB (OSTO:DMYD B), the current PS Ratio is 346.67 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of kr1.04 is trading 92.2% below its estimated GF Value™ of kr13.41.
GuruFocus considers Diamyd Medical AB to be Possible Value Trap.
Key valuation signals for OSTO:DMYD B:
PS Ratio: 346.67 (75% below median its 10-year median of 1,410.22)
GF Value™: kr13.41 vs. price of kr1.04 (92.2% below fair value)
Industry Position: 3488.7% above the Biotechnology median (#860 of 937)
No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
39GF Score
Get the complete analysis for OSTO:DMYD B
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DMYD B has been successfully added to your 
